Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial.
Authors
Griese, MatthiasCosta, Stefano
Linnemann, Rachel W
Mall, Marcus A
McKone, Edward F
Polineni, Deepika
Quon, Bradley S
Ringshausen, Felix C
Taylor-Cousar, Jennifer L
Withers, Nicholas J
Moskowitz, Samuel M
Daines, Cori L
Keywords
CYSTIC FIBROSISDRUG THERAPY
Metadata
Show full item recordJournal
American journal of respiratory and critical care medicineDOI
10.1164/rccm.202008-3176LEPubMed ID
32969708Item Type
ArticleLanguage
enEISSN
1535-4970ae974a485f413a2113503eed53cd6c53
10.1164/rccm.202008-3176LE
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Related articles
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
- Authors: Southern KW, Murphy J, Sinha IP, Nevitt SJ
- Issue date: 2020 Dec 17
- Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
- Authors: Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D, VX18-445-104 Study Group
- Issue date: 2021 Aug 26
- Efficacy of elexacaftor-tezacaftor-ivacaftor in portuguese adolescents and adults with cystic fibrosis carrying non-F508del variants.
- Authors: Pinto MO, Santos AS, Castanhinha S
- Issue date: 2024 Sep-Oct
- Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
- Authors: Çobanoğlu N, Özçelik U, Çakır E, Şişmanlar Eyüboğlu T, Pekcan S, Cinel G, Yalçın E, Kiper N, Emiralioğlu N, Şen V, Şen HS, Ercan Ö, Çokuğraş H, Kılınç AA, Al Shadfan LM, Yazan H, Altıntaş DU, Karagöz D, Demir E, Kartal Öztürk G, Bingöl A, Başaran AE, Sapan N, Çekiç Ş, Çelebioğlu E, Aslan AT, Gürsoy TR, Tuğcu G, Özdemir A, Harmancı K, Yıldırım GK, Köse M, Hangül M, Tamay Z, Süleyman A, Yüksel H, Yılmaz Ö, Özcan G, Topal E, Can D, Korkmaz Ekren P, Çaltepe G, Kılıç M, Özdoğan Ş, Doğru D
- Issue date: 2020 Sep
- Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis.
- Authors: Gonçalves Martynychen Canan M, Souza Sokoloski C, Rossetti Severo C, Zahi Rached S, Abensur Athanazio R
- Issue date: 2024 Aug